On 1/8/24, Travere Therapeutics Inc (NASDAQ: TVTX) stock enjoyed a major increase of 13.7%, closing at $9.82. Moreover, this advance was accompanied by above average trading volume at 147% of normal. Relative to the market the stock has been extremely weak over the last nine months but has risen 4.4% during the last week.
Current PriceTarget Research Rating
TVTX’s future returns on capital are forecasted to be in line with the cost of capital. Accordingly, the company is expected to continue to be Value Creation neutral.
Travere Therapeutics has a current Value Trend Rating of F (Lowest Rating). The Value Trend Rating reflects highly consistent signals from PTR’s two proprietary measures of a stock’s attractiveness. Travere Therapeutics has a very low Power Rating of 14 and a very low Appreciation Score of 2, producing the Lowest Value Trend Rating.
Rating Review
In light of this very positive price change we are reviewing our current Overall Rating of F. This review will be completed in the next several days.
Be the first to comment